- Home
- » Tags
- » Rivaroxaban
Top View
- Study Protocol
- Combining Antiplatelets and Anticoagulants Example
- Management of Bleeding in Patients Treated with Direct Oral Anticoagulants Marcel Levi1,2
- COVID-19 Vaccine Astrazeneca (Other Viral Vaccines) EPITT No:19683
- Rivaroxaban: a Fully-Subsidised Oral Anticoagulant
- Clinical Protocol
- IMPORTANT DRUG WARNING XARELTO® (Rivaroxaban) Film
- Guidance on Safe Switching of Warfarin to DOAC
- Prescriptions of Direct Oral Anticoagulants in Patients Admitted
- Bericht ATC-Code B01: Antithrombotische Mittel
- Rivaroxaban and Apixaban for DVTVTE Prophylaxis
- Rivaroxaban) Safely and Effectively
- A New Oral Anticoagulant in Cats by AMY
- Guidelines for Management of Patients on Rivaroxaban (Xarelto) Or Apixaban (Eliquis)
- Anticoagulation and Antiplatelet Update: a Case Based Approach
- Anti-Platelet and Anti-Coagulant Prescriptions and Breast Cancer Recurrence: a Danish Nationwide Prospective Cohort Study
- Rivaroxaban Handout – UC Davis 2013
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Oral Direct Thrombin Inhibitors Or Oral Factor Xa Inhibitors for the Treatment of Pulmonary Embolism (Review)
- Stable Coronary Artery Disease, Elective Stenting and Atrial Fibrillation
- Guidelines for Management of Bleeding with Dabigatran Or Rivaroxaban: for Possible Use in Local Management Protocols
- Xarelto (Rivaroxaban)
- Dabigatran, Rivaroxaban, Edoxaban and Apixaban for AF
- Oral Anticoagulants: Considerations for Use of Warfarin, Apixaban and Rivaroxaban
- Rivaroxaban (Xarelto®)
- On Absorption Modeling and Food Effect Prediction of Rivaroxaban, a BCS II Drug Orally Administered As an Immediate-Release Tablet
- Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
- Switching to and from Various Anticoagulants
- PIONEER AF-PCI: Rivaroxaban + P2Y12 Inhibitor Clopidogrel ~94% Or Rivaroxaban + DAPT Vs
- Monitoring Heparin Therapy and Measuring Direct Xa Inhibitors: Simple, Fast, 24/7
- Direct Oral Anticoagulants (Doacs) Guide
- ROCKET-AF: Rivaroxaban Vs Warfarin in Patients with Atrial Fibrillation
- Enoxaparin – Prescribing, Administration and Monitoring
- Rivaroxaban for Preventing Adverse Outcomes After Acute Management of Acute Coronary Syndrome
- Treatment for VTE with Apixaban Or Rivaroxaban in Adults
- Effects of Low Molecular Weight Heparin and Rivaroxaban on Rat Achilles Tendon Healing
- Xarelto, INN-Rivaroxaban
- Cdr Pharmacoeconomic Review Report for Xarelto
- Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: a Systematic Review of the Literature and Analysis of Vigibase
- Conversions (“Switching”) Among the Oral Anticoagulants
- Recanalisation Therapies for Acute Ischaemic Stroke in Patients On
- What Is Rivaroxaban (Xarelto)? a New Anticoagulant (“Blood Thinner”) That Reduces the Risk of Stroke (Blood
- Rivaroxaban (Xarelto), and Apixaban (Eliquis) September 2013 VHA Pharmacy Benefits Management Services, Medical Advisory Panel and VISN Pharmacist Executives
- Anticoagulant in Patients with Pulmonary Embolism and Fatty Liver: a Case Report
- Patients' Serum and Urine As Easily Accessible Samples for the Measurement of Non–Vitamin K Antagonist Oral Anticoagulants
- Topic 0518 Xarelto Vs. Lovenox for Prevention of VTE Following TJA
- Xarelto, INN-Rivaroxaban
- Xarelto® Dosing and Transition Management
- Rivaroxaban (Xarelto): What You Need to Know and Do
- Medicines for Stroke Prevention in Atrial Fibrillation Choosing the Right One for You
- XARELTO (Rivaroxaban) Tablets, for Oral Use • Treatment of DVT, PE, and Reduction in the Risk of Recurrence of Initial U.S
- Update on Anticoagulants Monitoring Practice
- Title: Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients with Symptomatic PAD